Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy
- PMID: 34654890
- PMCID: PMC8521595
- DOI: 10.1038/s41598-021-99950-1
Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy
Abstract
Cutaneous malignant melanoma is a rare but fatal disease in East Asia. Despite its increasing incidence, a general lack of awareness about the disease was noted. This study aims to provide population-based prognostic analysis of melanoma with sentinel lymph node biopsy (SLNB) in Taiwan. We conducted this retrospective cohort study using the data from Taiwan National Health Insurance Research Database during 1997-2013. The study cohort contains 3284 patients. The 5-year survival rates of patients undergoing SLNB and not undergoing SLNB were 45.5% and 33.6%. In multivariate analysis, age ≥ 80 years [adjusted hazard ratio (aHR) = 2.15] and male (aHR = 1.19) were associated with a poorer prognosis, while high social economic status (SES) (aHR = 0.69) and undergoing SLNB (aHR = 0.84) were good prognostic factors. Old age and low SES were associated with lower percentages of patients undergoing SLNB (P < 0.001). E-value analysis suggested robustness to unmeasured confounding. In conclusion, undergoing SLNB was associated with a better prognosis. The poor prognosis of old age and low SES may be due to decreased percentages of patients undergoing SLNB. Therefore, we recommend that SLNB should be performed on patients, especially in old age or low SES, who are candidates for SLNB according to current guidelines to achieve maximal survival.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy.J Formos Med Assoc. 2015 May;114(5):415-21. doi: 10.1016/j.jfma.2013.06.018. Epub 2013 Aug 19. J Formos Med Assoc. 2015. PMID: 23969039
-
Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.Cancer. 2012 Feb 15;118(4):1040-7. doi: 10.1002/cncr.26288. Epub 2011 Jul 19. Cancer. 2012. PMID: 21773971
-
Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System?J Am Coll Surg. 2019 Apr;228(4):466-472. doi: 10.1016/j.jamcollsurg.2018.12.030. Epub 2019 Jan 17. J Am Coll Surg. 2019. PMID: 30660817
-
Sentinel lymph node biopsy for melanoma: indications and rationale.Cancer Control. 2009 Jul;16(3):234-9. doi: 10.1177/107327480901600305. Cancer Control. 2009. PMID: 19556963 Review.
-
Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma?Laryngoscope. 2015 Jan;125(1):153-60. doi: 10.1002/lary.24807. Epub 2014 Jul 1. Laryngoscope. 2015. PMID: 24986770 Review.
Cited by
-
Construction and validation of machine learning models for predicting lymph node metastasis in cutaneous malignant melanoma: a large population-based study.Transl Cancer Res. 2025 Feb 28;14(2):706-716. doi: 10.21037/tcr-24-1672. Epub 2025 Feb 18. Transl Cancer Res. 2025. PMID: 40104720 Free PMC article.
-
A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan.Front Oncol. 2022 Mar 3;12:846760. doi: 10.3389/fonc.2022.846760. eCollection 2022. Front Oncol. 2022. PMID: 35311079 Free PMC article.
-
Machine learning to predict overall short-term mortality in cutaneous melanoma.Discov Oncol. 2023 Jan 31;14(1):13. doi: 10.1007/s12672-023-00622-5. Discov Oncol. 2023. PMID: 36719475 Free PMC article.
References
-
- Health Promotion Administration Ministry of Health and Welfare, T. Cancer Registry Annual Report, 2018 Taiwan https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/13498... (2020).
-
- Chang, J. W.-C. et al. Malignant melanoma in Taiwan: A prognostic study of 181 cases. Melanoma Res.14, 537-541 (2004). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical